IMPE Abstracts

ObjectivesGonadotropin-releasing hormone (GnRH) stimulation test is the gold standard test when diagnosing central precocious puberty (CPP). Gonadorelin (Relefact®) is used for the test but it is not always readily available and triptorelin can be used instead. The purpose of this study was to evaluate the diagnostic validity of triptorelin test compared to the GnRH test in diagnosing CPP.

MethodsA retrospective study was performed. One hundred girls with premature thelarche (PT) who underwent GnRH stimulation test were selected. Fifty girls were tested with intravenous gonadorelin (Relefact®) and the other half were tested with subcutaneous triptorelin acetate. Leutinizing hormone (LH), follicle-stimulating hormone (FSH) responses were measured at 30, 45, 60, 90 minutes after gonadorelin injection and 30, 60, 90, 120 minutes for the triptorelin injection.

ResultsClinical characteristics such as age, height, weight, body mass index, bone age were similar between two groups. Peak LH level was reached at 60 minutes after stimulation for both groups. Among the girls who were diagnosed with CPP, mean peak LH concentration was 8.15 mIU/mL and 9.73 mIU/mL for gonadorelin and triptorelin group respectively. 21% of the girls who underwent stimulation test with gonadorelin, and 23% percent of the triptorelin group were diagnosed with central precocious puberty (p value, 0.52).

ConclusionThe triptorelin test showed similar trends of LH elevation and diagnostic rate when compared to traditional GnRH test for diagnosing CPP. It suggests that the triptorelin test can be used as a valid alternative to the traditional GnRH test when differentiating CPP from PT. Our study also confirmed that Decapeptyl stimulation test up to 120 minutes was enough to make a diagnosis of CPP.